Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3884-3891

  Blum, William ^a   Klisovic, Rebecca B ^a   Hackanson, Bjoern ^a   Liu, Zhongfa ^a   Liu, Shujun ^a   Devine, Hollie ^a   Vukosavljevic, Tamara ^a   Huynh, Lenguyen ^a   Lozanski, Gerard ^a   Kefauver, Cheryl ^a   Plass, Christoph ^a   Devine, Steven M ^a   Heerema, Nyla A ^a   Murgo, Anthony ^a   Chan, Kenneth K ^a   Grever, Michael R ^a   Byrd, John C ^a   Marcucci, Guido ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTROGEN RECEPTOR; VALPROIC ACID; ANTINEOPLASTIC AGENT; AZACITIDINE; DRUG DERIVATIVE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; BRAIN DISEASE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GAIT DISORDER; HEMATOLOGIC DISEASE; HUMAN; KARYOTYPE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; MYELOID DIFFERENTIATION SYNDROME; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SOMNOLENCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; FATIGUE; INFECTION; MIDDLE AGED; NEUTROPENIA; REMISSION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BRAIN DISEASES; FATIGUE; HUMANS; INFECTION; LEUKEMIA, MYELOCYTIC, ACUTE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; TREATMENT FAILURE; VALPROIC ACID;

EID: 34548529948     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.4169     Document Type: Article

References (35)

1. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003
2. Ernst P, Wang J, Korsmeyer SJ: The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol 9:282-287, 2002
3. Hess JL: MLL: A histone methyltransferase disrupted in leukemia. Trends Mol Med 10:500-507, 2004
4. Li ZY, Liu DP, Liang CC: New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia 19:183-190, 2005
5. Redner RL, Wang J, Liu JM: Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 94:417-428, 1999
6. Whitman SP, Liu S, Vukosavljevic T, et al: The MLL partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106:345-352, 2005
7. Kurokawa M, Mitani K, Imai Y, et al: The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 92:4003-4012, 1998
8. Izutsu K, Kurokawa M, Imai Y, et al: The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 97:2815-2822, 2001
9. Sundqvist A, Sollerbrant K, Svensson C: The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. FEBS Lett 429:183-188, 1998
10. Kakizuka A, Miller WH Jr, Umesono K, et al: Chromosomal translocation t(15;17) in human acute promyelocyte leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-674, 1991
11. Grignani F, De Matteis S, Nervi C, et al: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818, 1998
12. Sirulnik A, Melnick A, Zelent A, et al: Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol 16:387-408, 2003
13. Carapeti M, Aguiar RC, Goldman JM, et al: A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91:3127-3133, 1998
14. Ogryzko W, Schiltz RL, Russanova V, et al: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959, 1996
15. Bannister AJ, Kouzarides T: The CBP coactivator is a histone acetyltransferase. Nature 384:641-643, 1996
16. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
17. Issa JP, Gharibyan V, Cortes J, et al: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23:3948-3956, 2005
18. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640, 2004
19. Yang AS, Doshi KD, Choi SW, et al: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495-5503, 2006
20. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007
21. Kuendgen A, Strupp C, Aivado M, et al: Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269, 2004
22. Kuendgen A, Schmid M, Schlenk R, et al: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106:112-119, 2006
23. Cameron EE, Bachman KE, Myohanen S, et al: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107, 1999
24. Klisovic MI, Maghraby EA, Parthun MR, et al: Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17: 350-358, 2003
25. Liu S, Shen T, Huynh L, et al: Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65:1277-1284, 2005
26. Gore SD, Baylin S, Sugar E, et al: Combined DNA Methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369, 2006
27. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al: Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 2006
28. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
29. Liu Z, Marcucci G, Byrd JC, et al: Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20:1117-1126, 2006
30. Liu Z, Liu S, Xie Z, et al: Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res 35:31, 2007
31. Raval A, Lucas DM, Matkovic JJ, et al: TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 23:3877-3885, 2005
32. Brena RM, Auer H, Kornacker K, et al: Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic Acids Res 34:e17, 2006
33. Farag SS, Archer KJ, Mrozek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006
34. Li Q, Kopecky KJ, Mohan A, et al: Estrogen receptor methylation is associated with improved survival in adult acuta myeloid leukemia. Clin Cancer Res 5:1077-1084, 1999
35. Agrawal S, Unterberg M, Koschmieder S, et al: DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 67:1370-1377, 2007